See more : Telefonaktiebolaget LM Ericsson (publ) (ERCB.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Lyell Immunopharma, Inc. (LYEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lyell Immunopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Montfort Capital Corp. (MONT.V) Income Statement Analysis – Financial Results
- Tele2 AB (publ) (TLTZY) Income Statement Analysis – Financial Results
- Foot Locker, Inc. (0IQK.L) Income Statement Analysis – Financial Results
- AMPD Ventures Inc. (AMPD.CN) Income Statement Analysis – Financial Results
- Oneview Healthcare PLC (ONE.AX) Income Statement Analysis – Financial Results
Lyell Immunopharma, Inc. (LYEL)
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 130.00K | 84.68M | 10.65M | 7.76M | 657.00K |
| Cost of Revenue | 0.00 | 16.47M | 14.54M | 7.48M | 0.00 |
| Gross Profit | 130.00K | 68.22M | -3.89M | 281.00K | 657.00K |
| Gross Profit Ratio | 100.00% | 80.55% | -36.48% | 3.62% | 100.00% |
| Research & Development | 182.95M | 159.19M | 138.69M | 182.24M | 63.60M |
| General & Administrative | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Other Expenses | -2.79M | 1.89M | -2.32M | -9.43M | -35.41M |
| Operating Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Cost & Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Interest Income | 23.45M | 7.05M | 1.17M | 5.94M | 8.12M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.25M | 16.47M | 14.54M | 7.48M | 4.38M |
| EBITDA | -226.76M | -166.65M | -199.94M | -207.64M | -100.83M |
| EBITDA Ratio | -174,429.23% | -194.96% | -1,546.53% | -2,677.19% | -15,347.49% |
| Operating Income | -247.01M | -183.12M | -214.78M | -211.94M | -102.09M |
| Operating Income Ratio | -190,006.15% | -216.24% | -2,016.68% | -2,732.56% | -15,538.66% |
| Total Other Income/Expenses | 12.38M | 3.84M | -36.65M | 7.47M | -27.29M |
| Income Before Tax | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Income Before Tax Ratio | -180,486.15% | -216.24% | -2,349.47% | -2,636.31% | -19,692.09% |
| Income Tax Expense | 0.00 | -178.36M | 35.28M | -5.94M | -8.12M |
| Net Income | -234.63M | -4.75M | -285.50M | -198.53M | -121.26M |
| Net Income Ratio | -180,486.15% | -5.61% | -2,680.76% | -2,559.73% | -18,456.01% |
| EPS | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| EPS Diluted | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| Weighted Avg Shares Out | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
| Weighted Avg Shares Out (Dil) | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
3 Penny Stocks to Buy With $500
Lyell Immunopharma Announces Participation in September Investor Conferences
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
Source: https://incomestatements.info
Category: Stock Reports